Welcome to our dedicated news page for Repligen (Ticker: RGEN), a resource for investors and traders seeking the latest updates and insights on Repligen.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Repligen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Repligen's position in the market.
Rhea-AI Summary
Repligen Corporation has announced the commercial launch of TangenX SC, the industry's first holder-free, self-contained Tangential Flow Filtration (TFF) device. This technology is suitable for the manufacture of biologics, including ADCs, viral vectors, nucleic acids, and lipid nanoparticles. TangenX SC offers advantages such as significant time savings, reduced risk of product loss, scalability, and single-use, gamma sterilized design.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.86%
Tags
-
News
Rhea-AI Summary
Repligen Corporation reported total third quarter revenues of $141.2 million, with base business revenues of $140.1 million. The company's order book strengthened, resulting in a total book-to-bill ratio of 1.07. Repligen also narrowed its full-year revenue guidance to a range of $635-$645 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.86%
Tags
-
Rhea-AI Summary
Repligen Corporation to report Q3 2023 financial results on October 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.75%
Tags
Rhea-AI Summary
Repligen Corporation appoints Olivier Loeillot as President and Chief Commercial Officer, strengthening executive team and driving growth
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.55%
Tags
-
Rhea-AI Summary
Repligen Corporation is set to acquire Metenova AB, a company known for its magnetic mixing technology in bioprocessing applications. Metenova is projected to generate revenues of $24 million to $25 million in 2023 and is expected to contribute $5 million in revenue to Repligen in Q4 2023. The acquisition is anticipated to be accretive to Repligen's adjusted gross and operating margins in 2024. Metenova's magnetic mixing technologies are designed to minimize product damage and improve product yield and consistency. The transaction is expected to be completed in the coming weeks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
-
Rhea-AI Summary
Repligen Corporation appoints Jason K. Garland as CFO, effective September 25, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.18%
Tags
Rhea-AI Summary
Repligen Corporation to present at Wells Fargo Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.05%
Tags
-
Rhea-AI Summary
Sartorius and Repligen Corporation have launched an integrated bioreactor system that incorporates Repligen XCell® ATF upstream intensification technology into Sartorius’ Biostat STR® bioreactor. The system simplifies intensified seed train and N perfusion implementation for biopharmaceutical manufacturers. It features a single direct control interface, optimized facility equipment installation, and reduced equipment footprint. Customers can easily purchase the integrated system with pretested and predefined configurations for faster delivery times.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.01%
Tags
-
News
Rhea-AI Summary
Repligen Corporation (NASDAQ:RGEN) reported Q2 2023 revenues of $159.2 million, down 23.3% YoY, and base business revenues of $157.1 million, down 8.7% YoY. The company adjusted its full-year revenue guidance to $635-$665 million, representing a YoY decrease of 17%-21%. Gross margin for Q2 2023 was 50.2%, compared to 58.5% in Q2 2022. Income from operations for Q2 2023 was $19.4 million, down 69.3% YoY. Net income for Q2 2023 was $20.1 million, down 59.7% YoY. Cash, cash equivalents, and short-term investments at June 30, 2023, were $603.7 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
Rhea-AI Summary
Repligen Corporation (NASDAQ:RGEN) will report its second quarter 2023 financial results on August 2, 2023, followed by a conference call and webcast to discuss business updates and financial results for the three- and six-month reporting periods ended June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
Repligen Corp
Nasdaq:RGEN
RGEN Rankings
RGEN Stock Data
9.29B
51.95M
6.59%
105.58%
8.54%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
United States of America
WALTHAM
About RGEN
repligen corporation is a life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs. our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. we are a leading manufacturer of protein a, a critical reagent used to manufacture monoclonal antibody-based therapeutics. we also supply several growth factor products used to increase cell culture productivity in biomanufacturing. in the burgeoning area of disposable biomanufacturing technologies, we have developed and market a series of opus™ (open platform user specified) single-use chromatography columns used in the biologics purification process. repligen’s corporate headquarters are located in waltham, ma, usa; we have an additional manufacturing facility in lund, sweden.